RT Journal Article
SR Electronic
T1 Pregnancy Outcome in Multiple Sclerosis Patients Exposed to Disease Modifying Therapies. (P4.2-100)
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP P4.2-100
VO 92
IS 15 Supplement
A1 Ahmed, Samar Farouk
A1 Almuteri, Manal L.
A1 Al-Hashel, Jasem
A1 Alroughani, Raed
YR 2019
UL http://n.neurology.org/content/92/15_Supplement/P4.2-100.abstract
AB Objective: To evaluate pregnancy outcomes in Multiple Sclerosis (MS) patients exposed to disease modifying therapies (DMTs).Background: MS patients may be exposed to DMTs during the first trimester in unplanned pregnancies or while using high efficacy drugs in patients at risk of disease reactivation.Design/Methods: Data of MS pregnant women was extracted from the national MS registry. Details of drug exposure and pregnancy outcomes were collected. The occurrence of spontaneous/ elective abortions and fetal malformation were obtained. Pregnancy outcomes in women who were exposed to DMTs were compared to women who discontinued DMTs prior to conception.Results: Outcomes of 142 pregnancies (120 women) were assessed; 80 (56.3%) of which were exposed to DMTs. At the time of pregnancy confirmation, mean age and mean disease duration were 20.5 ± 4.7 and 5 ± 4.2 years respectively. There were no significant differences between DMT-exposed pregnancies and the non-exposed in terms of mean age (p= 0.95), age at onset (p= 0.84), age at pregnancy confirmation (p= 0.37) or disease duration (p= 0.35). In the exposed group, the most used DMTs were beta interferons (n=50; 35.2%), natalizumab (n=28; 19.7%), fingolimod (n=24; 16.9%), and dimethyl fumarate (n=5; 3.5%). In the non-exposed group, 53.2% (n=33) of patients were not on DMTs, while 21% (n=13) were on fingolimod, 19.4% (n=12) were on beta interferons and 4.8% (n=3) were on dimethylfumarate. Most pregnancies (~85%) resulted in full term births. There were no significant differences between the exposed and non-exposed in the rate of premature birth (5% versus 3.2%) and abortions (10% versus 11.3%) [p= 0.47]. No major fetal malformations were reported.Conclusions: Most of the pregnancies in our cohort were exposed to disease modifying therapies. The pregnancy outcomes in patients exposed to DMTs is comparable to those were not exposed.Disclosure: Dr. Ahmed has nothing to disclose. Dr. Almuteri has nothing to disclose. Dr. Al-Hashel has nothing to disclose. Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Biologix, Genpharm, Glaxo SmithKline, Lundbeck, Merck Serono, Novartis, and Sanofi. Dr. Alroughani has received research support from Bayer, Biogen, Biologix, Genpharm, Glaxo SmithKline, Lundbeck, Merck Serono, Novartis, and Sanofi.